Wroclaw, Poland Clinical Trials

A listing of Wroclaw, Poland clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 202 clinical trials
Featured trial
Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and/or Cancer

The University of Tennessee Health Science Center in Memphis, TN has a research opportunity for people to participate in the study: Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and Cancer. Specifically, they are looking for individuals over the age of 60 for 1 of 3 groups: (1) those …

primary cancer
AIDS
Online studies
cancer
University of Tennessee Health Science Center
(online study) Contact site
  • 41 views
  • 28 Sep, 2022
  • 1 location
  • Online study
Featured trial
ARE YOU CARING FOR A LOVED ONE WITH DEMENTIA OR MCI?

You may be eligible to participate in a research study evaluating the effects of a new in-hometechnology system for caregivers of people with dementia or mild cognitive impairment. Thestudy is being conducted by Dr. Robert Levenson (University of California, Berkeley,Department of Psychology) and Gene Wang (People Power Company of Care …

cognitive impairment
Online studies
alzheimer's disease
dementia
mild cognitive impairment
University of California, Berkeley
(online study) Contact site
  • 48 views
  • 05 Dec, 2022
  • 1 location
  • Online study
Featured trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.

Investigative Site PL002
 (1.8 away) Contact site
  • 16 views
  • 28 Oct, 2022
  • +31 other locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.

rituximab
marginal zone lymphoma
follicular lymphoma
lenalidomide
Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego
 (1.3 away) Contact site
  • 5 views
  • 27 Oct, 2022
  • +197 other locations
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod (ARTIOS)

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.

dimethyl fumarate
fingolimod
ofatumumab
Novartis Investigative Site
 (1.4 away) Contact site
  • 183 views
  • 16 Oct, 2022
  • +135 other locations
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Patients With Primary Progressive Multiple Sclerosis. (FENtrepid)

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (or placebo) or intravenous (IV) ocrelizumab (or placebo) in a blinded fashion through an interactive voice …

Wro Medica
 (2.8 away) Contact site
  • 0 views
  • 18 Oct, 2022
  • +144 other locations
A Phase 2a/2b, Multicenter, Randomized, Placebo and Active Comparator-controlled, Double-Blind, Dose-ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa (LYRA)

The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).

abscess
adalimumab
Centrum Medyczne Matusiak w CITYCLINICPrzychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
 (1.6 away) Contact site
  • 177 views
  • 17 Oct, 2022
  • +53 other locations
A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of NAH

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of …

Uniwersytecki Szpital Kliniczny UM we Wroclawiu
 (2.3 away) Contact site
  • 17 views
  • 17 Oct, 2022
  • +97 other locations
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (DB-06)

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

Research Site
 (113.2 away) Contact site
  • 215 views
  • 19 Oct, 2022
  • +248 other locations
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Specjalistyczna przychodnia lekarska POLIMED
 (1.6 away) Contact site
  • 88 views
  • 19 Oct, 2022
  • +327 other locations